Xilio Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase I/II clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment.
[Xilio Therapeutics, Inc.]
7992332
{7992332:BBBBBBBB}
apa
50
1
170953
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
